
|Articles|March 1, 2004
Satisfactory response
Washington - Etanercept can be safely administered to AIDS patients with difficult-to-treat inflammatory conditions, according to Robert Wallis, associate professor of medicine at UMDNJ-NJMS, who presented a poster at the February 2004 AAD meeting describing results of a Phase I trial conducted in Kampala, Uganda. "There does not appear to be a substantial risk that either opportunistic infections or HIV disease will be deleteriously affected by this treatment," said Dr. Wallis.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clinicians Weigh Topical Sequencing and Escalation in Complex Atopic Dermatitis Cases
2
Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease
3
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
4
Common Mistakes in Managing Hair Loss and Pigmentary Disorders
5











